Overview

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-11-15

Target enrollment:

Participant gender:

Summary

This phase II MATCH treatment trial tests how well crizotinib works in treating patients with solid tumors, lymphoma, or multiple myeloma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that does not respond to treatment (refractory) and who have MET gene amplification. Crizotinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of enzymes that cancer cells need to grow and spread. It may also prevent the growth of new blood vessels that tumors need to grow.

Phase:

PHASE2

Details

Lead Sponsor:

National Cancer Institute (NCI)

Treatments:

Biopsy
Crizotinib
Specimen Handling
X-Rays